Details for Patent: 12,509,443

« Back to Dashboard

Which drugs does patent 12,509,443 protect, and when does it expire?

Patent 12,509,443 protects ROMVIMZA and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 12,509,443

Title:	CSF-1R inhibitors and methods of use thereof
Abstract:	Provided herein, in part, is a compound of Formula (I) or a hydrate thereof, essentially free of one or more impurities, compositions thereof, and methods of use thereof.
Inventor(s):	Elena Kostik, Ann Gelormini, Michael D. Kaufman
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US19/299,588
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 12,509,443

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-001	Feb 14, 2025		RX	Yes	No			Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-002	Feb 14, 2025		RX	Yes	No			Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes			Y

International Family Members for US Patent 12,509,443

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Taiwan	202608865
World Intellectual Property Organization (WIPO)	2025231106